(Registrieren)

EANS-Adhoc: LifeWatch confirms receipt of a request from a shareholder group to include additional motions in the agenda of the AGM (with document)

Geschrieben am 02-04-2013

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Annual & Special Corporate Meetings/Company Information/LifeWatch AG
02.04.2013

Neuhausen am Rheinfall/Switzerland - The Board of Directors of
LifeWatch AG (SIX Swiss Exchange: LIFE), confirms receipt of a letter
signed by Patrik Ringler on behalf of a shareholder group, requesting
additional motions to be included in the agenda of the ordinary
Annual General Meeting (AGM) 2013.

The request submitted in due time asks for the partial amendment of
the articles of incorporation in the sense of the recently adopted
Minder initiative in Switzerland and for the election of Antoine
Hubert and Dr. Stephan Rietiker as additional members of the Board of
Directors of LifeWatch AG.

The Board of Directors of LifeWatch AG will consider the requests of
the group during the preparation of the AGM. The full agenda of the
AGM will be published in due time, i.e. at the latest 20 days prior
to the AGM which will take place on Wednesday, May 29, 2013 in
Zurich.

About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on
SIX Swiss Exchange (LIFE), Switzerland, is the leading healthcare
technology and solution company, specializing in advanced telehealth
systems and wireless remote patient monitoring services. LifeWatch
services cater to individuals, ranging from high-risk and chronically
ill patients, to consumers of health and wellness products. LifeWatch
AG has operative subsidiaries in the United States, in Switzerland
and in Israel and is the parent company of LifeWatch Services Inc.,
and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a
leading US-based provider of cardiac monitoring services and home
sleep testing of Obstructive Sleep Apnea (OSA). LifeWatch
Technologies Ltd., based in Israel, is a leading developer and
manufacturer of telemedicine products. The Company is planning to
introduce the LifeWatch V, an Android-based smartphone with medical
sensors and apps that uses a cloud-based service platform. For
additional information, please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is
available at http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding future results of
operations and financial position, business strategy and plans and
objectives for future operations, are forward- looking statements.
The words "believe," "may," "will," "estimate,"
"continue,""anticipate," "intend,""expect" and similar expressions
are intended to identify forward-looking statements. LifeWatch AG has
based these forward-looking statements largely on current
expectations and projections about future events and financial trends
that it believes may affect the financial condition, results of
operations, business strategy, short term and long term business
operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions. In light of these risks, uncertainties and assumptions,
the forward-looking events and circumstances described may not occur
and actual results could differ materially and adversely from those
anticipated or implied in the forward- looking statements. All
forward-looking statements are based only on data available to
LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise.

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF
AMERICA AND SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR
PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THIS
PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF SECURITIES OF LIFEWATCH
AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN THE UNITED STATES OR AN
INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES OF LIFEWATCH
AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN
REGISTERED UNDER THE UNITED STATES SECURITIES LAWS AND MAY NOT BE
OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES OR TO U.S.
PERSONS ABSENT REGISTRATION UNDER OR AN APPLICABLE EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE UNITED STATES SECURITIES LAWS. ANY
PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED STATES WILL BE
MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH AG
OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED
INFORMATION ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL
STATEMENTS OF THE ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/YgQnBzd2

Further inquiry note:
Sensus Communication Consultants, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email lifewatch@sensus.ch

end of announcement euro adhoc
--------------------------------------------------------------------------------

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/YgQnBzd2


issuer: LifeWatch AG
Rundbuckstrasse 6
CH-8212 Neuhausen am Rheinfall
phone: +41 52 632 00 50
FAX: +41 52 632 00 51
mail: users@lifewatch.com
WWW: www.lifewatch.com
sector: Healthcare Providers
ISIN: CH0012815459
indexes: SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
SIX Swiss Exchange
language: English


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

455740

weitere Artikel:
  • EANS-News: Value Management & Research AG kündigt Kapitalrückzahlung von EUR 4,00 je Aktie für den 12. April 2013 an -------------------------------------------------------------------------------- Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. -------------------------------------------------------------------------------- Kapitalmaßnahmen/Kapitalrückzahlung Kronberg (euro adhoc) - Die ordentliche Hauptversammlung der Value Management & Research AG hatte am 12. September 2012 beschlossen, das Grundkapital der Gesellschaft von EUR 8.032.825 um EUR 6.426.260 auf EUR 1.606.565 nach den mehr...

  • EANS-Adhoc: Rekordergebnis der Vienna Insurance Group im Jahr 2012 -------------------------------------------------------------------------------- Ad-hoc-Mitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Geschäftszahlen/Bilanz 03.04.2013 - Höchster Gewinn der Unternehmensgeschichte - Gewinn vor Steuern steigt um 5,1 Prozent auf 587,4 Mio. Euro - Gewinn (nach Steuern und Minderheiten) wächst um 9,7 Prozent auf 446,2 Mio. Euro mehr...

  • EANS-Adhoc: Record result of Vienna Insurance Group in 2012 -------------------------------------------------------------------------------- ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Financial Figures/Balance Sheet 03.04.2013 - Highest profit in the corporate history - Profit before taxes increased by 5.1 percent to EUR 587.4 million - Profit (after taxes and minorities) grew by 9.7 percent mehr...

  • EANS-News: Epigenomics AG / Epigenomics AG: Dr. Uwe Staub Appointed to the Executive Board -------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Company Information/Board of Directors (Appointments and Changes) Berlin, Germany, and U.S.A. (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that Dr. Uwe Staub, mehr...

  • EANS-News: Epigenomics AG / Epigenomics AG ernennt Dr. Uwe Staub zum Vorstandsmitglied -------------------------------------------------------------------------------- Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. -------------------------------------------------------------------------------- Unternehmen/Vorstand/Personalie Berlin, Deutschland und USA (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), das deutsch-amerikanische Krebsdiagnostik-Unternehmen, gab heute bekannt, dass Dr. Uwe Staub, Chief Operating Officer (COO) des Unternehmens, mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht